

## Special Issue

# Periprosthetic Joint Infection: Understanding the Epidemiology, Pathogenesis, Diagnosis and Treatment Options

### Message from the Guest Editors

As you are all aware, periprosthetic joint infection (PJI) is a devastating complication and one of the leading causes of implant failure following primary and revision total-joint arthroplasty (TJA). Concurrently, the economic burden of this disease process exceeds \$2 billion per annum in the United States alone. Notwithstanding this, our understanding of PJI epidemiology, pathogenesis, diagnosis, and treatment options remains limited. We are excited to be collaborating with *Antibiotics* to bring you this Special Issue on PJI. All articles related to the epidemiology, pathogenesis, diagnosis, and treatment of PJI will be considered for publication, including clinical research, fundamental scientific research, and systematic reviews. In order to be considered for publication in this Special Issue, all articles must be submitted by the deadline date of 31 May 2025.

---

### Guest Editors

Dr. Saad Tarabichi

Mayo Clinic Orthopaedics, Scottsdale, AZ, USA

Dr. Mark J. Spangehl

Mayo Clinic Orthopaedics, Scottsdale, AZ, USA

Dr. Joshua S. Bingham

Mayo Clinic Orthopaedics, Scottsdale, AZ, USA

---

### Deadline for manuscript submissions

31 May 2026



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/223415](https://mdpi.com/si/223415)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)